TORONTO, April 11 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced its financial and operational results for the first fiscal quarter of 2008, ended February 29, 2008.
"During the quarter, we continued to focus on advancing our antibody
drugs efficiently and rapidly towards human clinical trials. Most
significantly, we completed our pre-IND meeting with the US FDA for our
lead CD44 Cancer Stem Program," said Dr. David Young, President and CEO of
ARIUS. "We also presented new findings from our lead programs, including
data from our CD9 Cancer Stem Cell program in collaboration with Dr. John
Dick, a pioneer in the cancer stem cell field. Maintaining this momentum,
five ARIUS abstracts have been selected for presentation in the upcoming
AACR Annual meeting this month, demonstrating the scientific community's
ongoing interest in our programs and the high quality of our research."
CD44 Cancer Stem Cell Program
- Selected to present two CD44-focused posters at AACR the American
Association for Cancer Research (AACR) Annual Meeting held from
April 12-16, 2008 in San Diego, California.
- Held meeting with FDA to discuss plans for the upcoming
- Prepared to file a Phase I IND application and begin human
clinical trials for the CD44 Cancer Stem Cell program in 2008.
Trop-2 Signal Transduction Program
- Completed first toxicology studies.
- Selected to present a Trop-2-focused poster at AACR Annual
- Engaged Laureate Pharma Inc. for cGMP manufacturing of humanized
antibody for Phase 1 clinical supply. A cell line producing the
humanized anti-Trop-2 antibody was successfully transferred to
|SOURCE ARIUS Research Inc.|
Copyright©2008 PR Newswire.
All rights reserved